Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides compounds of formula I:
wherein G is a small group selected from hydrogen or C1-3 alkyl, Q is pyridine or pyrimidine, and R1-R3 are as defined in the specification. These compounds are selective JNK inhibitors showing good activity against the three isoforms of JNK (JNK1, JNK2 and JNK3) and relatively low activity against p38 kinase. The compounds are therefore useful for treating JNK-mediated diseases, especially neurodegenerative diseases in which all three JNK isoforms are implicated.
113 Citations
16 Claims
- 1. A compound of formula I:
-
6. A compound selected from the compounds listed in Table 1.
- 7. A method for treating a disease or condition in a mammal that is alleviated by treatment with a JNK kinase inhibitor, comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound of formula I:
Specification